Dexcom provided a look at new data for the upcoming generation of its continuous glucose monitoring sensor. Presenting at the J.P. Morgan Healthcare Conference, the details were pulled from a large ...

Dexcom has obtained European approval for the latest generation of its wearable diabetes sensor, the G7 continuous glucose monitor, for adults and children ages two and up. Designed to be 60% smaller ...

After months of international availability, the Dexcom G7 constant glucose monitor received its FDA clearance to distribute in the US. Ahead of the wide rollout, we got to go hands-on with a demo ...

The Dexcom G7 continuous glucose monitor (CGM) is as accurate or better than other currently marketed CGM devices for measuring glucose in those with diabetes, new data from a pivotal study suggest.

The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It's the longest-lasting system on the market. The G7 ...

At the conference, first-ever accuracy and performance data will be presented for Dexcom's upcoming G7 15 Day system,1 showing an overall mean absolute relative difference (MARD) of 8.0%, making ...

While still a couple of years out, MD+DI gained some insights into Dexcom's next-generation sensor from an interview with the ...

DexCom, Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy and hold forever. On September 22, UBS reiterated a ‘Buy’ rating on the stock and a $106 price target. The research firm reiterated ...

Dexcom announced last week that its G7 continuous glucose monitoring system has received FDA clearance. The latest model of its CGM, which can be used by people with all types of diabetes ages 2 and ...